Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5700 - Early Palliative care in advanced cancer, is it really effective?

Date

28 Sep 2019

Session

Poster Display session 1

Topics

End-of-Life Care

Tumour Site

Presenters

Raquel Gómez Bravo

Citation

Annals of Oncology (2019) 30 (suppl_5): v661-v666. 10.1093/annonc/mdz261

Authors

R. Gómez Bravo1, J.C. Sánchez González1, B. Núñez García1, A.M. Morito Aguilar1, F. García Recio2, A. Ruano Raviña3, M. Méndez García4, B. Cantos5, M. Provencio4

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Puerta de Hierro - Majadahonda, 28222 - Majadahonda/ES
  • 2 Palliative Care, Hospital Universitario Puerta de Hierro - Majadahonda, 28222 - Majadahonda/ES
  • 3 Medicina Preventiva Y Salud Pública, Universidad de Santiago de Compostela, 15701 - Santiago de Compostela/ES
  • 4 Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 - Majadahonda/ES
  • 5 Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, 28035 - Madrid/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5700

Background

Palliative care units (PCU) have shown an improvement in the quality of life of patients with cancer by reducing overtreatments at the end of life and increasing symptomatic care at home, avoiding unnecessary emergency room visits and decreasing the number of hospital admissions.

Methods

A retrospective observational study was conducted, selecting all patients with a first consultation in the Medical Oncology Unit of the Puerta de Hierro University Hospital (HUPdH) between 2014 and 2015 and died before December 31st 2017. Assessment by PCU, number of hospital admissions and re-admissions and most frequent symptoms for admission in the last 6 months of life were reviewed. The main objective was to know if there were differences between those who were valued by PCU or not.

Results

A total of 662 patients were selected. From them, 86 (13%) patients had never been admitted at HUPdH, 312 (47%) had been admitted once, 169 (26%) twice and 95 (14%) three or more times. Before death, 474 (72%) had been valued by PCU and 302 did not received PCU visit before the second hospital admission episode. The three most frequent causes of admission were deterioration of the general condition, infections and uncontrollable pain. In those with an assessment by PCU before the second admission process, there was a significant decrease in the number of readmissions (25% versus 68%). Moreover, in these patients, there was a statistically significant decrease in the number of re-admissions because of the three main causes of admission but also in others, such as dyspnea, neurological worsening, bleeding and nauseas and vomiting. (Table).Table:

1606P

PCU: Percentage of patients re-admitted with an assessment by palliative care unit by the time of re-admission; Non PCU: Percentage of patients re-admitted without assessment by palliative care units before re-admission
SymptomPCUNon PCURisk Ratio
Deterioration of the general condition9%21%RR 0.41, 95% CI 0.27-061, p < 0.0001
Dyspnea3%13%RR 0.24, 95% CI 0.12-0.45, p < 0.0001
Neurological worsening2%8%RR 0.25, 95% CI 0.11-0.56, p < 0.0001
Infections5%24%RR 0.20, 95% CI 0.12-0.32, p < 0.0001
Uncontrollable pain5%15%RR 0.35, 95% CI 0.21-0.59, p < 0.001
Nauseas and vomiting2%7%RR 0.32, 95% CI 0.14-0.71, p < 0.003
Bleeding2%7%RR 0.34, 95% CI 0.15-0.75%, p < 0.005

Conclusions

In our cohort, in patients with an assessment by PCU before the second admission episode, was observed a decrease in number and severity of re-admissions. An optimization of the symptomatic treatment at home implies a decrease in hospital-acquired or nosocomial complications which leads to a reduction in costs and above all, an improvement in the quality life both of patients and their families.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.